Evidence map›Paper›PMID 39126557›Full record

ArticleAIDS and behavior2024

Weighing the Options: Which PrEP (Pre-exposure Prophylaxis) Modality Attributes Influence Choice for Young Gay and Bisexual Men in the United States?

Jonathan Hill-Rorie, Katie B Biello, Meg Quint, Bernadette Johnson, Latesha Elopre, Kendra Johnson, Rebecca Lillis, Kaylee Burgan, Douglas Krakower, Yohance Whiteside and 1 more

Abstract read
In one paragraph

Article in AIDS and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jonathan Hill-RorieThe Fenway Institute, Fenway Health, Boston, MA, USA.
Katie B BielloThe Fenway Institute, Fenway Health, Boston, MA, USA. katie_biello@brown.edu.ORCID http://orcid.org/0000-0002-5017-5699
Meg QuintThe Fenway Institute, Fenway Health, Boston, MA, USA.
Bernadette JohnsonUniversity of Alabama, Birmingham, Birmingham, AL, USA.
Latesha ElopreUniversity of Alabama, Birmingham, Birmingham, AL, USA.
Kendra JohnsonUniversity of Mississippi Medical Center, Jackson, MS, USA.
Rebecca LillisLouisiana State University School of Medicine, New Orleans, LA, USA.
Kaylee BurganUniversity of Alabama, Birmingham, Birmingham, AL, USA.
Douglas KrakowerThe Fenway Institute, Fenway Health, Boston, MA, USA.
Yohance WhitesideMerck & Co., Inc., Rahway, NJ, USA.
Kenneth H MayerThe Fenway Institute, Fenway Health, Boston, MA, USA.

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases P30AI042853Merck MerckNIAID NIH HHS P30 AI042853
6 · The paper itself

Abstract

Pre-exposure prophylaxis (PrEP) is effective in preventing HIV transmission, but uptake and adherence among young men who have sex with men (YMSM) remains suboptimal. New PrEP formulations may enhance PrEP use, but little is known about their acceptability. We enrolled 39 cis- and transgender YMSM (age 18-34) from Boston, MA; Jackson, MS; Birmingham, AL; and New Orleans, LA, who participated in video-based focus groups (n = 30) or in-depth interviews (n = 9) to examine how new PrEP products (e.g., injections, monthly pills, implants) are perceived and might be improved for YMSM. Focus groups were transcribed, coded, and analyzed using grounded theory and content analysis. Nearly half (46%) of participants were Black; 11% identified as Hispanic. Seventy-nine percent were PrEP experienced. Product preference was driven by the desire for flexible, safe, effective, and affordable PrEP options. A majority of participants preferred subcutaneous injections every 6 months or monthly pills dispersed in 3 or 4 doses. Subcutaneous injections and batched monthly pills were favored by those with demanding schedules and those who desired fewer provider visits; monthly pills were more appealing for those who feared needles. Despite broad preferences for longer-acting products for convenience, participants raised concerns regarding side effects and waning protection after missed doses. Participants felt that more education about safety and efficacy profiles of new products could influence their attitudes. These findings suggest that it is important to prioritize YMSM's dynamic lifestyles during product development, and that product safety and efficacy information should be accessible in youth-friendly language.

Indexed as

Anti-HIV AgentsFocus GroupsHIV InfectionsHomosexuality, MalePre-Exposure ProphylaxisSexual and Gender MinoritiesAdolescentAdultBisexualityChoice BehaviorHumansInterviews as TopicMalePatient Acceptance of Health CareQualitative ResearchUnited StatesAnti-HIV AgentsHIVLong-Acting PrEPNext Generation PrEPPrEPProduct PreferenceYMSM

Identifiers

PMID39126557
PMCPMC13003522

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.